Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIT-(BCMA+CD19)-CAR-T Cells in Relapsed/Refractory Autoimmune Diseases
NCT07604792Phase 1Withdrawn
- Sponsor
- Beijing Boren Hospital
- Start
- Sep 2025
- Primary completion
- Nov 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Autologous CD19-BCMA dual-target CAR T-cell therapy in autoimmune disease, sponsored by Beijing Boren Hospital. Primary endpoint: Incidence of dose-limiting toxicity at 28 days. Planned start Sep 2025; status: withdrawn.
02
Drugs
Autologous CD19-BCMA dual-target CAR T-cell therapy
03
Conditions
autoimmune disease
Beyond the preview
Go deeper on NCT07604792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07604792.